The team at Harvard Medical School’s Laboratory of Systems Pharmacology are focused on cancer and on analyzing the ways cancer drugs affect the whole body. They aim to reinvent the drug development process through this systems approach, by going much deeper than would scientists supervising a typical clinical trial and by establishing a new model of collaboration. Peter Sorger, head of the Program in Therapeutic Science and professor of systems pharmacology, and Jerry Lin, research fellow in systems biology, are quoted.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure